Humacyte Class Action Lawsuit Alert: Bragar Eagel & Squire, P.C. Notice

A class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) in the United States District Court for the Southern District of New York. The lawsuit alleges that the Company made false and misleading statements regarding its business and prospects, leading to financial harm for investors.

According to the complaint, Humacyte failed to disclose that its key product, HUMACYL, was not in compliance with regulatory standards and faced an increased risk of being withdrawn from the market. This information came to light when the FDA issued a Form 483 to the Company, highlighting deficiencies in its manufacturing processes and product quality control.

As a result of this news, Humacyte’s stock price plummeted, causing significant financial losses for shareholders. The lawsuit seeks to recover damages for investors who purchased Humacyte stock between December 13, 2021, and October 11, 2022.

Investors who believe they may have been affected by the alleged misconduct are encouraged to contact the law firm representing the class action lawsuit to participate in the legal proceedings. It is important for investors to stay informed about such developments, as they can have a significant impact on their financial well-being.

In conclusion, the class action lawsuit against Humacyte serves as a reminder of the importance of transparency and accountability in the financial markets. Investors should always conduct thorough research and due diligence before investing in any company to mitigate the risks of potential losses.